GoAI
Get started
GridAI Technologies Corp. logo

GridAI Technologies Corp.

GRDX

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$3.569

−$0.181 · -4.83%

Aug 21, 4:00 PM ET

Pre-market

$3.47

−$0.099 · -2.77%

Aug 24, 8:51 AM ET

GRDX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

8

Overpriced

Momentum

62

Gaining

Sentiment

50

Mixed

Risk resilience

29

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

GridAI Technologies Corp. functions as a clinical-stage biopharmaceutical enterprise primarily dedicated to developing precise, locally-acting treatments for various digestive system ailments. Its core activity involves researching and advancing therapeutic solutions specifically designed for patients with gastrointestinal diseases. The company's pipeline features several key drug candidates, including Latiglutenase, Capeserod, Adrulipase, and Niclosamide. GridAI Technologies was established on January 30, 2014, and maintains its principal offices in Boca Raton, Florida.

Industry
Biotechnology
Sector
Healthcare
Headquarters
GB
CEO
Jason David Sawyer
Listed since
Oct 11, 2016
Employees
2

Market position

Day range

Current $3.569

52-week range

Current $3.569

Open
$3.74
Previous close
$3.75
Volume
123.05K
1.08× average
Average volume
113.67K
Average daily volume
Market cap
12M USD
Beta
1.87
Market reference 1
50-day average
$3.903
-8.56% below average
200-day average
$3.3463
+6.66% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
8.9M USD
P/E (TTM)
-0.55×
P/B (TTM)
1.25×
P/S (TTM)
74.83×
EV / EBITDA
-1.37×
Earnings yield
-84.85%
Free cash flow yield
-75.70%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-741.40%
Operating margin
-7655.42%
Net margin
-4932.44%
Return on equity
-26.96%
Return on assets
-13.17%
Return on invested capital
-18.67%

Financial health

Debt / equity
0.1×
Current ratio
0.17×

Financial statements

Income trends

Operating income

−7.08M USD+54.66%

Net income

−6.39M USD+64.60%
Income trends across reported periods−1.13M USD−22.19M USD−43.26M USD−64.32M USDOperating income, FY2021: −59.06M USDOperating income, FY2022: −12.68M USDOperating income, FY2023: −15.77M USDOperating income, FY2024: −15.62M USDOperating income, FY2025: −7.08M USDNet income, FY2021: −58.54M USDNet income, FY2022: −14.63M USDNet income, FY2023: −15.79M USDNet income, FY2024: −18.06M USDNet income, FY2025: −6.39M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −59.06M USD. Operating income FY2022 −12.68M USD. Operating income FY2023 −15.77M USD. Operating income FY2024 −15.62M USD. Operating income FY2025 −7.08M USD. Net income FY2021 −58.54M USD. Net income FY2022 −14.63M USD. Net income FY2023 −15.79M USD. Net income FY2024 −18.06M USD. Net income FY2025 −6.39M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue36.25K USD————
Cost of goods sold1.27M USD48.95K USD29.27K USD106.21K USD537.4K USD
Gross profit−1.23M USD−48.95K USD−29.27K USD−106.21K USD−537.4K USD
Research and development925.48K USD903.94 USD5.03M USD691.26K USD38.32M USD
Selling, general, and administrative5.5M USD14.72M USD10.74M USD11.99M USD18.38M USD
Operating expenses5.85M USD15.62M USD15.77M USD12.68M USD59.06M USD
Interest income—875 USD2.53K USD8.42K USD1.17K USD
Interest expense490.84K USD—22.46K USD15.88K USD11.24K USD
Depreciation and amortization574.71K USD48.95K USD29.27K USD29.27K USD542.26K USD
Operating income−7.08M USD−15.62M USD−15.77M USD−12.68M USD−59.06M USD
Net income−6.39M USD−18.06M USD−15.79M USD−14.63M USD−58.54M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
56%
5 beats, 4 misses, 0 met estimates
Average EPS surprise
-1099.86%
9 comparable reports
Latest EPS result
-0.44
Estimate -11,340 · Beat by 100.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.12-4,082.48-8,164.83-12,247.19Q2 '25MissQ2 '25BeatQ3 '25No estimateQ4 '25No estimateQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q2 2025, reported Apr 4, 2025: actual -13.19, estimate -0.41, surprise -3115.85%, Miss. Q2 2025, reported May 15, 2025: actual -0.28, estimate -2.31, surprise +87.88%, Beat. Q3 2025, reported Aug 14, 2025: actual -0.14, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 19, 2025: actual -0.64, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 25, 2026: actual -2.92, estimate -11,340, surprise +99.97%, Beat. Q2 2026, reported May 27, 2026: actual -0.82, estimate -11,340, surprise +99.99%, Beat. Q3 2026, reported Aug 21, 2026: actual -0.44, estimate -11,340, surprise +100.00%, Beat. Q4 2026, reported Nov 16, 2026: actual —, estimate -11,340, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates100.54K77.52K54.51K31.49KQ2 '25No estimateQ1 '26MetQ2 '26MetQ3 '26MetQ4 '26Estimate
Q2 2025, reported Apr 4, 2025: actual 95.78K USD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 25, 2026: actual 36.25K USD, estimate 36.25K USD, surprise 0.00%, Met estimate. Q2 2026, reported May 27, 2026: actual 38.21K USD, estimate 38.21K USD, surprise 0.00%, Met estimate. Q3 2026, reported Aug 21, 2026: actual 85.88K USD, estimate 85.88K USD, surprise 0.00%, Met estimate. Q4 2026, reported Nov 16, 2026: actual —, estimate 85.88K USD, surprise —, Comparison unavailable.

GRDX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding GRDX

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
214.77K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Dimensional - US Sustainability Core 1 ETF logoDimensional - US Sustainability Core 1 ETFDFSU
Market value
9.12K
Weight
0.00%
AUM
2.35B USD
Expense ratio
0.15%
Price / 1D
$48.20+0.52%

Continue in GoAI

Research GRDX

research.disclaimer